Turner Investments’s Achillion Pharmaceuticals ACHN Stock Holding History

Turner Investments’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-56,920	Closed	-$261K	–	246
2017 Q2	$261K	Sell	56,920 -8,500	-13%	-$34.2K	0.17%	160
2017 Q1	$275K	Sell	65,420 -18,260	-22%	-$75.8K	0.18%	154
2016 Q4	$346K	Sell	83,680 -879,130	-91%	-$4.67M	0.14%	180
2016 Q3	$7.8M	Buy	962,810 +107,240	+13%	+$912K	2.58%	1
2016 Q2	$6.67M	Sell	855,570 -3,990	-0.5%	-$34.2K	2.09%	4
2016 Q1	$6.64M	Sell	859,560 -51,450	-6%	-$377K	1.8%	4
2015 Q4	$9.83M	Sell	911,010 -174,990	-16%	-$1.59M	2.03%	3
2015 Q3	$7.5M	Buy	1,086,000 +534,040	+97%	+$4.35M	1.52%	7
2015 Q2	$4.89M	Buy	+551,960	New	+$5.22M	0.89%	26
2015 Q1	–	Sell	-32,930	Closed	-$403K	–	553
2014 Q4	$403K	Buy	+32,930	New	+$402K	0.05%	363

Other funds holding ACHN

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Turner Investments's ACHN Position: Q3 2017 in Review

Turner Investments sold out of Achillion Pharmaceuticals (ACHN) in Q3 2017, closing a stake of 56,920 shares — an estimated $261K sold.

Turner Investments first reported a position in ACHN in Q4 2014 and held it in 10 quarters. The position peaked at $9.83M in Q4 2015. 125 funds tracked by Wall St. Rank hold ACHN as of Q3 2017.

Turner Investments reported no remaining Achillion Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Turner Investments sold 56,920 Achillion Pharmaceuticals shares in Q3 2017, an estimated $261K.
Turner Investments first reported a position in Achillion Pharmaceuticals in Q4 2014 and held it in 10 quarters.
Turner Investments's Achillion Pharmaceuticals position peaked at $9.83M in Q4 2015.
125 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q3 2017.

Based on Turner Investments's 13F filing for Q3 2017, filed 8 Nov 2017.